Skip to main content
Back
Watch Compare

Aligos Therapeutics, Inc.

Data quality: 100%
ALGS
Nasdaq Manufacturing Chemicals
$7.97
▼ $0.02 (-0.25%)
Mkt Cap: 49.32 M
Price
$7.97
Mkt Cap
49.32 M
Day Range
$7.77 — $8.06
52-Week Range
$3.76 — $13.69
Volume
10,996
Open $7.96
50D / 200D Avg
$7.27
9.60% above
50D / 200D Avg
$8.68
8.16% below

Quick Summary

Key Takeaways

Negative free cash flow of -82.50 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)-39.46%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-27.86%
Above sector avg (-51.02%)
ROIC-68.75%
Net Margin-1106.72%
Op. Margin-4024.93%

Safety

Debt / Equity
N/A
Current Ratio4.70
Interest Coverage-39.99

Valuation

PE (TTM)
-2.04
Below sector avg (-1.98)
P/B Ratio0.69
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (44 peers)
Metric Stock Sector Median
P/E -2.0 -2.0
P/B 0.7 5.1
ROE % -27.9 -51.0
Net Margin % -1106.7 -150.2
Rev Growth 5Y % — 9.3
D/E — 0.3

ETFs Holding This Stock

AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0.00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -39.46% Revenue Growth (3Y) -40.58%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2.19 M Net Income (TTM) -24.19 M
ROE -27.86% ROA -19.79%
Gross Margin N/A Operating Margin -4024.93%
Net Margin -1106.72% Free Cash Flow (TTM) -82.50 M
ROIC -68.75% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4.70
Interest Coverage -39.99 Asset Turnover 0.02
Working Capital 81.45 M Tangible Book Value 71.83 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2.04 Forward P/E N/A
P/B Ratio 0.69 P/S Ratio 22.56
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -167.29%
Market Cap 49.32 M Enterprise Value 7.37 M
Per Share
EPS (Diluted TTM) -2.45 Revenue / Share 0.35
FCF / Share -13.33 OCF / Share -13.33
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 341.02%
SBC-Adj. FCF -88.13 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2.19 M 3.61 M 6.19 M 0.0 0.0
Net Income -24.19 M -131.21 M -87.68 M -96.05 M -128.33 M
EPS (Diluted) -2.45 -20.94 -1.36 — —
Gross Profit — — — — —
Operating Income -87.99 M -89.15 M -88.13 M -97.58 M -128.32 M
EBITDA — — — — —
R&D Expenses 69.45 M 70.27 M 73.04 M 85.08 M 104.15 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 2.20 M 1.70 M 4.30 M — —
Income Tax 314,000.0 331,000.0 795,000.0 106,000.0 143,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 88.53 M 70.09 M 151.53 M 146.69 M 235.37 M
Total Liabilities 34.99 M 99.07 M 59.45 M 42.79 M 50.64 M
Shareholders' Equity 53.55 M -28.97 M 92.08 M 103.90 M 184.73 M
Total Debt — — — — —
Cash & Equivalents 18.30 M 37.00 M 135.70 M 81.35 M 186.82 M
Current Assets 82.86 M 62.14 M 141.08 M 133.55 M 204.42 M
Current Liabilities 21.23 M 21.74 M 23.91 M 33.13 M 38.96 M